Literature DB >> 25604328

Visceral leishmaniasis as an independent cause of high immune activation, T-cell senescence, and lack of immune recovery in virologically suppressed HIV-1-coinfected patients.

J L Casado1, M Abad-Fernández, S Moreno, M J Pérez-Elías, A Moreno, J I Bernardino, A Vallejo.   

Abstract

OBJECTIVES: Different immune alterations have been described in HIV-infected patients with visceral leishmaniasis (VL). We aimed to identify the immunological factors involved in the lack of immunological recovery and VL relapses in HIV-infected patients with VL, by comparison with other HIV-infected patients.
METHODS: We carried out a cross-sectional study of 55 patients receiving suppressive combination antiretroviral therapy (cART) for at least 1 year: nine with previous relapsing VL, 20 with an immunodiscordant response (IDR) to cART (CD4 count < 200 cells/μL) and no previous VL, and 26 with a concordant response (CR) to cART (CD4 count > 350 cells/μL) without VL. Immunosenescence was investigated by analysing CD57(+) CD28(-) levels, immune activation by analysing CD38(+) HLA-DR(+) levels, inflammation by analysing interleukin (IL)-6 levels, and microbial translocation by analysing lipopolysaccharide (LPS) and soluble CD14 (sCD14) levels.
RESULTS: In VL patients, the median time since VL diagnosis was 42 months, and all patients had had at least one relapse despite suppressive cART for a median time of 43 months. Patients with previously diagnosed VL had a higher CD8 T-cell activation level (P < 0.001) than those with IDR. Also, levels of IL-6, LPS and especially sCD14, associated with bacterial translocation and additional monocyte activation, were significantly increased in patients with previous VL compared with patients with IDR (P = 0.048, P = 0.049 and P < 0.001, respectively). In addition, patients with previous VL had higher levels of CD8 T-cell senescence. Notably, the levels of immune activation and inflammation in patients with previous VL were not related to the time of VL diagnosis, the number of VL relapses, or hepatitis C virus (HCV) coinfection.
CONCLUSIONS: Our data demonstrate that VL patients had an even worse immunological status than patients with IDR, which was probably associated with increased microbial translocation and additional monocyte/macrophage activation. These data explain the observed lack of immunological recovery and the occurrence of VL relapses in HIV-infected patients with previous VL.
© 2015 British HIV Association.

Entities:  

Keywords:  HIV; immune activation; immunodiscordance; immunosenescence; leishmaniasis

Mesh:

Year:  2015        PMID: 25604328     DOI: 10.1111/hiv.12206

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  12 in total

1.  Visceral Leishmaniasis in Hospitalized HIV-Infected Patients in Pernambuco, Brazil.

Authors:  Diego Lins Guedes; Zulma Medeiros; Elis Dionísio da Silva; Audrey Violeta Martins de Vasconcelos; Mariana Santana da Silva; Maria Almerice Lopes da Silva; Paulo Sérgio Ramos de Araújo; Demócrito de Barros Miranda-Filho
Journal:  Am J Trop Med Hyg       Date:  2018-12       Impact factor: 2.345

2.  Sexually transmitted infections and immune activation among HIV-infected but virally suppressed youth on antiretroviral therapy.

Authors:  Tanya L Kowalczyk Mullins; Su X Li; James Bethel; Maureen M Goodenow; Stephanie Hudey; John W Sleasman
Journal:  J Clin Virol       Date:  2018-02-07       Impact factor: 3.168

3.  Risk Factors for Death from Visceral Leishmaniasis in an Urban Area of Brazil.

Authors:  Angelita F Druzian; Albert S de Souza; Diogo N de Campos; Julio Croda; Minoru G Higa; Maria Elizabeth C Dorval; Mauricio A Pompilio; Polliana A de Oliveira; Anamaria M M Paniago
Journal:  PLoS Negl Trop Dis       Date:  2015-08-14

4.  Immune Activation and Bacterial Translocation: A Link between Impaired Immune Recovery and Frequent Visceral Leishmaniasis Relapses in HIV-Infected Patients.

Authors:  Maria Luciana Silva-Freitas; Glaucia Fernandes Cota; Talia S Machado-de-Assis; Carmem Giacoia-Gripp; Ana Rabello; Alda M Da-Cruz; Joanna R Santos-Oliveira
Journal:  PLoS One       Date:  2016-12-01       Impact factor: 3.240

5.  Adaptive NKG2C+CD57+ Natural Killer Cell and Tim-3 Expression During Viral Infections.

Authors:  Hassen Kared; Serena Martelli; Shu Wen Tan; Yannick Simoni; Meng Li Chong; Siew Hwei Yap; Evan W Newell; Sylvia L F Pender; Adeeba Kamarulzaman; Reena Rajasuriar; Anis Larbi
Journal:  Front Immunol       Date:  2018-04-20       Impact factor: 7.561

Review 6.  Visceral leishmaniasis and HIV coinfection: current perspectives.

Authors:  José Angelo Lauletta Lindoso; Carlos Henrique Valente Moreira; Mirella Alves Cunha; Igor Thiago Queiroz
Journal:  HIV AIDS (Auckl)       Date:  2018-10-15

7.  Serum Levels of Soluble CD40 Ligand and Neopterin in HIV Coinfected Asymptomatic and Symptomatic Visceral Leishmaniasis Patients.

Authors:  Wim Adriaensen; Saïd Abdellati; Saskia van Henten; Yonas Gedamu; Ermias Diro; Florian Vogt; Bewketu Mengesha; Emebet Adem; Luc Kestens; Johan van Griensven
Journal:  Front Cell Infect Microbiol       Date:  2018-12-11       Impact factor: 5.293

8.  Relapse of visceral leishmaniasis in an HIV-infected patient successfully treated with a combination of miltefosine and amphotericin B.

Authors:  Shauna McQuarrie; Ken Kasper; Dana C Moffatt; Daniel Marko; Yoav Keynan
Journal:  Can J Infect Dis Med Microbiol       Date:  2015 Nov-Dec       Impact factor: 2.471

Review 9.  Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients.

Authors:  Wim Adriaensen; Thomas P C Dorlo; Guido Vanham; Luc Kestens; Paul M Kaye; Johan van Griensven
Journal:  Front Immunol       Date:  2018-01-12       Impact factor: 7.561

10.  Microbial Translocation Does Not Drive Immune Activation in Ugandan Children Infected With HIV.

Authors:  Felicity C Fitzgerald; Edouard Lhomme; Kathryn Harris; Julia Kenny; Ronan Doyle; Cissy Kityo; Liam P Shaw; George Abongomera; Victor Musiime; Adrian Cook; Julianne R Brown; Anthony Brooks; Ellen Owen-Powell; Diana M Gibb; Andrew J Prendergast; A Sarah Walker; Rodolphe Thiebaut; Nigel Klein
Journal:  J Infect Dis       Date:  2019-01-01       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.